Biogen

Human Immunology Biosciences is a biotechnology company dedicated to developing therapies for immune-mediated diseases, particularly autoimmune and inflammatory conditions. The company specializes in precision medicine and focuses on discovering and creating transformative therapies. Its lead product, felzartamab, is a fully human anti-CD38 monoclonal antibody that has demonstrated the ability to deplete CD38+ cells, including plasma cells and natural killer cells, in clinical studies. This mechanism may enhance clinical outcomes across a range of immune-mediated diseases, offering improved treatment options for patients suffering from these conditions.

Reata Pharmaceuticals is a clinical-stage biopharmaceutical company that develops innovative therapeutics aimed at treating serious and life-threatening diseases by targeting molecular pathways involved in cellular metabolism and inflammation. The company is advancing several clinical trial programs, including bardoxolone methyl for chronic kidney disease related to Alport syndrome and pulmonary arterial hypertension, as well as omaveloxolone for Friedreich’s ataxia. Additionally, Reata is conducting studies for various forms of chronic kidney disease, including IgA nephropathy and diabetic kidney disease. The company is also developing RTA 901 for neurological conditions such as diabetic neuropathy and exploring RORgT inhibitors in preclinical stages for autoimmune and fibrotic diseases. Reata has strategic collaborations with Kyowa Kirin to develop bardoxolone in several Asian markets and with AbbVie to research second-generation Nrf2 activators for various indications. Founded in 2002 and headquartered in Plano, Texas, Reata Pharmaceuticals was previously known as Reata Discovery, Inc. until its name change in 2005.

Autobahn Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule therapies for central nervous system (CNS) disorders. Since its incorporation in 2017, Autobahn has aimed to address significant unmet needs in neuropsychiatry and neuroimmunology through its innovative brain-targeting chemistry platform. The company's leading candidate, ABX-002, is a thyroid hormone receptor beta agonist being investigated as a potential treatment for multiple sclerosis and adrenomyeloneuropathy, as well as an adjunctive therapy for major depressive disorder and bipolar disorder depression. Autobahn Therapeutics emphasizes precision tuning of CNS exposure, targeting validated clinical and biological markers to enhance therapeutic opportunities and patient outcomes.

Accure Health is a privately held precision medicine company dedicated to developing AI-powered solutions that utilize patients' biomarker profiles. The company aims to enhance the delivery of precision therapies by ensuring that treatments are directed to the appropriate cells for the right patients. Accure Health's patented technologies integrate advanced protein design, an automated biomarker device, and a scalable, food-based production system. This innovative approach focuses on improving the targeted delivery of RNA and protein therapeutics, thereby facilitating access to more effective treatments tailored to individual patient needs.

SAGE Therapeutics is a biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders. The company's lead product is ZULRESSO, an intravenous formulation of brexanolone designed for treating postpartum depression. SAGE's pipeline includes several advanced candidates, such as SAGE-217, currently in Phase III trials for various depressive disorders and anxiety, and SAGE-324, which is in Phase II trials for essential tremors. Additionally, SAGE-718 is being explored for multiple conditions, including depression and Alzheimer's disease, having completed its Phase I trials. The company has established strategic collaborations with Shionogi & Co., Ltd. and Biogen Inc. to enhance the development and commercialization of its therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts, SAGE Therapeutics aims to address significant unmet needs in brain health through its scientific innovations and partnerships.

Autobahn Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule therapies for central nervous system (CNS) disorders. Since its incorporation in 2017, Autobahn has aimed to address significant unmet needs in neuropsychiatry and neuroimmunology through its innovative brain-targeting chemistry platform. The company's leading candidate, ABX-002, is a thyroid hormone receptor beta agonist being investigated as a potential treatment for multiple sclerosis and adrenomyeloneuropathy, as well as an adjunctive therapy for major depressive disorder and bipolar disorder depression. Autobahn Therapeutics emphasizes precision tuning of CNS exposure, targeting validated clinical and biological markers to enhance therapeutic opportunities and patient outcomes.

CAMP4 Therapeutics Corporation, based in Cambridge, Massachusetts, specializes in bioinformatics and gene regulation circuitry. Founded in 2015, the company has developed a 4-D gene circuitry platform that translates the activation of the human genome's 24,000 genes into a set of combinatorial rules based on existing signaling pathways. This innovative approach allows CAMP4 to control gene expression effectively, addressing the root causes of diseases. By leveraging this gene circuitry code, the company aims to expedite the drug development process, significantly reducing both time and risk associated with bringing new treatments to patients.

Nightstar Therapeutics plc is a clinical-stage gene therapy company based in London, focused on developing innovative one-time treatments for rare inherited retinal diseases. The company’s lead product candidate, NSR-REP1, is currently in phase 3 clinical development for choroideremia, while NSR-RPGR is undergoing phase 2/3 trials for X-linked retinitis pigmentosa. Additionally, Nightstar is developing NSR-BEST1 and NSR-ABCA4, with the latter in preclinical development for Stargardt disease. Founded in 2017, Nightstar Therapeutics aims to address the unmet medical needs of patients suffering from these conditions.

Samsung Bioepis Co., Ltd. is a biopharmaceutical company based in Incheon, South Korea, specializing in the development and production of biosimilar products. Established in 2012, the company aims to enhance patient access to high-quality treatment options through its extensive pipeline of biosimilar candidates. Samsung Bioepis focuses on innovative therapies targeting various health conditions, including neurodegenerative diseases, hemophilia, and autoimmune disorders. The company has formed a strategic collaboration with Takeda Pharmaceutical Company, further strengthening its position in the biopharmaceutical industry. By leveraging process innovation, Samsung Bioepis strives to provide improved healthcare solutions for patients worldwide.

Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with high unmet medical needs. With its unique Reverse Translational Medicine™ platform, Neurimmune creates recombinant human-derived monoclonal antibodies with biophysical characteristics closely resembling those occurring in healthy elderly. These antibodies display unique properties such as target selectivity, superior pharmacodynamics and low immunogenicity, resulting in superior risk profiles and excellent efficacy. Neurimmune’s pipeline comprises programs for a broad variety of disease related targets and specific target conformations. These include misfolded, oligomeric, fibrillar or post-translationally modified forms of disease-associated proteins as well as physiological conformations involved in major disease pathways.

Remedy Pharmaceuticals, Inc. is a clinical stage pharmaceutical company based in New York, founded in 2004. The company is dedicated to developing small molecule drugs aimed at addressing acute central nervous system disorders, such as stroke, traumatic brain injury, spinal cord injury, and organ ischemia. Remedy Pharmaceuticals leverages its expertise in targeting NCCa-ATP channels to create innovative therapies, including RP-1127, an intravenous formulation of glyburide, which acts as an inhibitor of these channels. By focusing on these critical areas, the company aims to provide effective treatment options for patients suffering from severe nervous system-related conditions.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Rodin Therapeutics is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapeutics for cognitive disorders through the application of epigenetic insights. Founded in 2013 with backing from Atlas Venture and Johnson & Johnson Development Corporation, the company leverages advanced structural biology capabilities and a team experienced in central nervous system (CNS) drug development. Rodin's innovative approach centers on the modulation of histone deacetylase (HDAC) complexes to restore synaptic function and promote neuronal health in degenerative brain diseases. This strategy aims to address significant unmet medical needs in the treatment of neurological disorders. As of November 2019, Rodin operates as a subsidiary of Alkermes Inc.

Convergence Pharmaceuticals is an independent biotechnology company established in October 2010 after acquiring specific neuroscience clinical assets from GlaxoSmithKline. The company specializes in the development of innovative analgesics, focusing on small molecule sodium channel blockers designed to address neuropathic pain. Its pipeline includes differentiated clinical-stage compounds that target key points in chronic pain signaling through the modulation of specific ion channels, aiming to achieve favorable efficacy, responder rates, and side effect profiles.

True North Therapeutics, Inc. is a biotechnology company focused on developing therapies that target the complement pathway of the immune system, specifically for rare diseases with high unmet clinical needs. Founded in 2013 and based in South San Francisco, California, the company’s lead product, TNT009, is a monoclonal antibody designed to selectively inhibit the classical complement pathway. This approach aims to prevent inflammatory mediators and phagocytosis in conditions such as cold agglutinin disease, warm autoimmune hemolytic anemia, and other complement-mediated disorders. True North is also exploring additional treatment options for a variety of diseases in hematology, dermatology, and neurology. The company operates as a subsidiary of Bioverativ Inc.

Ataxion is a discovery-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapies for rare and underserved neurologic diseases. Founded in April 2013 by Dr. Josh Resnick and David Grayzel, MD, through the Atlas Venture seed program, Ataxion specializes in small-molecule therapeutics that target hereditary ataxia and other degenerative neurological disorders such as multiple sclerosis and Huntington's disease. By leveraging ion-channel modulators, the company aims to provide effective treatments for patients suffering from these debilitating conditions.

Stromedix is a biopharmaceutical company dedicated to developing therapies for organ failure due to fibrosis. Initially, it will concentrate on chronic indications, utilizing its expertise to remodel tissues affected by this condition. In the future, Stromedix plans to expand its therapeutic pipeline to address related areas, including acute organ failure and cancer. Through its innovative approach, the company aims to provide effective treatments that improve patient outcomes in these challenging medical contexts.

TYSABRI is a prescription medication designed to treat adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It is administered as an infusion every four weeks, making it a less frequent option compared to daily or weekly treatments. While TYSABRI can be effective for patients who have not responded to other therapies or whose physical disability has worsened, it carries a risk of progressive multifocal leukoencephalopathy (PML). Therefore, it is crucial for patients to discuss the potential benefits and risks of TYSABRI with their healthcare provider before starting treatment. With nearly 400,000 individuals in the United States affected by MS, TYSABRI represents a significant option in the evolving landscape of MS therapies.

Knopp Biosciences LLC is a biotech company based in Pittsburgh, Pennsylvania, established in 2004. The company is dedicated to discovering and developing innovative medicines for inflammatory and neurological diseases. Its product portfolio includes dexpramipexole, an anti-inflammatory therapeutic aimed at modulating white blood cells, alongside a hematology discovery program focused on selectively arresting eosinophil maturation to treat inflammatory conditions. Knopp also has a preclinical KCNQ2 program targeting a genetic mutation linked to neonatal encephalopathy and related disorders, as well as a mitochondrial discovery initiative that seeks small molecule modulators to enhance mitochondrial efficiency. By focusing on diseases that impose significant burdens on the healthcare system and utilizing validated biomarkers and genetic testing, Knopp Biosciences aims to accelerate treatment development and improve patient outcomes.

The Museum of Science, founded in 1830, is one of the largest science centers in the world and the most visited cultural institution in New England, attracting over 1.5 million visitors annually. It offers a comprehensive exploration of science, technology, engineering, and math (STEM) through engaging programs and hundreds of interactive exhibits. Notable attractions include the Thomson Theater of Electricity, Charles Hayden Planetarium, Mugar Omni Theater, Gordon Current Science & Technology Center, 3-D Digital Cinema, and a Butterfly Garden. The Museum plays a significant role in education, reaching 25,000 teens globally through the Intel Computer Clubhouse Network and leading a National Science Foundation-funded initiative to enhance informal science education. Its acclaimed "Science Is an Activity" exhibit plan has received numerous NSF grants and has influenced science centers internationally. Additionally, the Museum's National Center for Technological Literacy® has developed engineering curricula that have benefited over 40,600 teachers and nearly 3 million students across the United States.

Vivoryon Therapeutics AG is a clinical stage biopharmaceutical company based in Halle, Germany, specializing in the research and development of therapeutic products for Alzheimer's disease and cancer. The company's lead candidate, PQ912, is a small molecule QC inhibitor that has completed Phase IIb clinical trials for Alzheimer's disease and is also being explored for cancer treatment. Additionally, Vivoryon is developing PQ1565, a small molecule inhibitor targeting glutaminyl-peptide cyclotransferase-like for cancer therapy, along with a monoclonal antibody aimed at enhancing the clearance of toxic pyroglutamate-Abeta. The company collaborates with various institutions, including the University Medical Center Schleswig-Holstein and Nordic Bioscience, to advance its clinical and research initiatives. Originally founded in 1997 as Probiodrug AG, the company rebranded to Vivoryon Therapeutics AG in June 2019.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, founded in 2003. It specializes in developing and commercializing innovative therapeutics primarily aimed at treating thrombosis, hematologic disorders, and inflammation. The company's lead product is Andexxa, an antidote for the anticoagulants rivaroxaban and apixaban. Additionally, Portola offers Bevyxxa, a once-daily oral Factor Xa inhibitor designed to prevent venous thromboembolism in adults with acute medical conditions. The firm is also developing several investigational products, including cerdulatinib, an oral dual inhibitor for hematologic cancers, and other compounds targeting chronic inflammatory diseases and cardiovascular conditions. Portola engages in collaborative agreements with various pharmaceutical companies to enhance its research and development efforts. As of July 2020, it operates as a subsidiary of Alexion Pharmaceuticals, Inc.

iPierian is a biotechnology company specializing in the development of therapies for neurodegenerative diseases. Utilizing induced pluripotent stem cells, the company focuses on addressing significant unmet medical needs, particularly in conditions such as spinal muscular atrophy, amyotrophic lateral sclerosis, and Parkinson's disease. iPierian is engaged in the research and development of innovative therapies, including monoclonal antibodies aimed at treating Alzheimer's disease and other Tauopathies. By targeting the mechanisms that drive disease progression, the company aims to provide physicians with effective tools to slow the spread of Tau in the brain, thereby potentially improving patient outcomes.

Knopp Biosciences LLC is a biotech company based in Pittsburgh, Pennsylvania, established in 2004. The company is dedicated to discovering and developing innovative medicines for inflammatory and neurological diseases. Its product portfolio includes dexpramipexole, an anti-inflammatory therapeutic aimed at modulating white blood cells, alongside a hematology discovery program focused on selectively arresting eosinophil maturation to treat inflammatory conditions. Knopp also has a preclinical KCNQ2 program targeting a genetic mutation linked to neonatal encephalopathy and related disorders, as well as a mitochondrial discovery initiative that seeks small molecule modulators to enhance mitochondrial efficiency. By focusing on diseases that impose significant burdens on the healthcare system and utilizing validated biomarkers and genetic testing, Knopp Biosciences aims to accelerate treatment development and improve patient outcomes.

Virdante Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the development and commercialization of drugs for autoimmune and inflammatory diseases. Founded in 2007 and previously known as Centaurus Pharmaceuticals, the company specializes in creating antibody and Fc-fusion therapies aimed at addressing various autoimmune conditions. Through its innovative research and development efforts, Virdante Pharmaceuticals seeks to improve treatment options for patients suffering from these disorders.

Intellikine is engaged in the discovery and development of small molecule therapies that specifically target the PI3K/Akt/mTOR signaling pathway. The company focuses on creating innovative drug candidates aimed at treating various conditions, including cancer, inflammation, and autoimmune disorders. Its product lineup features INK128, an orally available TORC1/2 inhibitor designed for solid tumor malignancies, and INK1197, a dual PI3K selective inhibitor intended for patients suffering from immune-mediated inflammatory diseases like rheumatoid arthritis and asthma. Intellikine is dedicated to assembling a talented team and an effective discovery platform to accelerate the development of next-generation medical breakthroughs in kinase inhibitor therapies.

Hydra Biosciences is a biopharmaceutical company located in Cambridge, Massachusetts, focused on developing innovative drugs for pain, inflammation, cardiovascular diseases, and other conditions. The company utilizes its expertise in novel ion channels, specifically targeting Transient Receptor Potential (TRP) ion channels, to create selective and safer therapeutic options. Hydra employs proprietary high-throughput screening platforms that facilitate the identification and development of drug candidates aimed at addressing significant unmet medical needs. With a strong intellectual property portfolio and a flexible approach to drug discovery, Hydra differentiates itself from traditional biopharmaceutical firms. The company has attracted substantial financing from notable investors, enabling it to advance its drug development programs effectively.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in the field, the company focuses on the specific inhibition of calcium release-activated calcium channels. This innovative approach seeks to modulate the immune response and protect against tissue cell injury, addressing significant unmet medical needs in life-threatening inflammatory conditions for which existing therapies are lacking. CalciMedica's proprietary technology has the potential to offer therapeutic benefits in these challenging areas of healthcare.

Resolvyx Pharmaceuticals is developing an entirely new class of medicines called Resolvins. Resolvins are naturally-occurring, small molecule lipid mediators with the potential to treat a wide range of inflammatory diseases. Unlike most anti-inflammatory drugs which suppress the body's inflammatory response, Resolvins work by activating the body's own mechanisms for shutting off, or resolving, inflammation.

Provasculon is a biotechnology company focused on developing novel therapeutic proteins aimed at healing organs damaged by ischemia. Founded based on the discoveries of Richard Lee, MD, and Vincent Segers, MD, both affiliated with Brigham and Women's Hospital, Provasculon specializes in innovative applications of Stromal Cell-Derived Factor-1 (SDF-1). The company's lead therapeutic protein shows promise in restoring the function of hearts severely affected by ischemic conditions, potentially bringing them back to near normal performance. Through its research and development efforts, Provasculon seeks to address critical medical needs in the treatment of ischemic organ damage.

PanGenetics B.V., based in Utrecht, Netherlands, specializes in the development of monoclonal antibodies aimed at treating immune-mediated diseases. The company focuses on advancing antibodies from late-stage research to clinical proof of concept, utilizing a lean business model that outsources manufacturing and clinical development to specialized providers. Among its clinical programs is PG110, along with PG102, a CD40 antagonist currently undergoing evaluation in a clinical study for patients with psoriatic arthritis. Additionally, PanGenetics employs an in-licensing model to expand its portfolio of antibody-based therapeutic products. The company's strategic approach allows it to concentrate on its core competencies while leveraging external expertise for other critical functions.

Escoublac Inc. is a biotechnology company based out of Cambridge, Massachusetts, United States.

Syntonix Pharmaceuticals is a biopharmaceutical company based in Waltham, Massachusetts, specializing in the discovery and development of novel, long-acting therapeutic products for chronic diseases like hemophilia, anemia, and autoimmune disorders. The company utilizes proprietary Fc-fusion proteins and engineered ligands to enhance drug delivery and efficacy. Syntonix focuses on developing selected products independently while partnering with established companies for others. With a team of experienced professionals, Syntonix aims to improve existing drugs by leveraging its innovative technology. The company operates out of a state-of-the-art 25,000 square foot laboratory facility, including a cGMP clinical manufacturing suite.

Fumapharm is a privately held pharmaceutical company focused on the development of therapeutic products derived from fumaric acid esters. The company specializes in creating treatments for psoriasis, aiming to offer effective solutions for patients suffering from this chronic skin condition. Through its research and development efforts, Fumapharm is dedicated to advancing medical therapies that address the needs of individuals affected by psoriasis.

MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, specializing in the discovery and development of antibody-based therapeutics for cancer treatment. Founded in 2000, the company focuses on immuno-oncology and has a diverse pipeline of product candidates. Key developments include Margetuximab, a monoclonal antibody in Phase III clinical trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other investigational products include MGA012, MGD013, MGD019, and Enoblituzumab, which target various immune checkpoints and tumor-associated antigens. MacroGenics is also advancing combination therapies and antibody-drug conjugates, such as MGC018, which targets solid tumors expressing B7-H3. The company has formed strategic collaborations with notable partners, enhancing its research and development efforts in the biopharmaceutical landscape.

Conforma Therapeutics Corporation designs and develops drugs for the treatment of cancer. It develops drugs that induce tumor cells to degrade the proteins that promote cancer growth. The company offers HSP90 and CNF1010 which are used for the treatment of cancer. The company was incorporated in 1999 and is based in San Diego, California

GlobeImmune, Inc. is a biopharmaceutical company based in Louisville, Colorado, dedicated to developing therapeutic products for cancer and infectious diseases through its proprietary Tarmogen platform. The company’s pipeline includes GS-4774, currently in Phase 2 trials for hepatitis B virus treatment, and various candidates targeting cancer, such as GI-6207 for medullary thyroid cancer, GI-6301 for tumors expressing the brachyury protein, and GI-4000 for resected pancreatic cancer. Additionally, GlobeImmune is advancing several candidates for infectious diseases, including GI-19000 for tuberculosis, GI-2010 for HIV, and GI-18000 for hepatitis D virus, currently in preclinical stages. The Tarmogen platform also includes products designed to address challenges in cancer therapy, such as preventing the emergence of mutated escape variants. The company has established strategic collaborations with Gilead Sciences and Celgene Corporation. Originally founded as Ceres Pharmaceuticals in 1995, GlobeImmune changed its name in 2001 to reflect its focus on innovative immunotherapy solutions.

Raven biotechnologies, Inc., a biotechnology company, focuses on the development of monoclonal antibody therapeutics for treating cancer. Its lead product candidate, RAV12, targets adenocarcinomas and used for the treatment of gastrointestinal, lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. The company was founded in 1999 and is based in South San Francisco, California. As of July 17, 2008, Raven Biotechnologies, Inc. operates as a subsidiary of MacroGenics, Inc.

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing targeted inhibitors for treating various cancers, both hematologic and solid. Its lead candidate, vecabrutinib, is a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor currently undergoing Phase 1b/2 clinical trials for chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also advancing SNS-510, which is in preclinical studies for solid tumors and hematologic malignancies. Additionally, Sunesis is involved in partnered programs, including TAK-580, a pan-Raf inhibitor in Phase 1 trials for pediatric low-grade glioma, and vosaroxin, an anti-cancer agent that affects DNA and inhibits topoisomerase II. Collaborative efforts with Biogen Idec and Takeda Pharmaceutical focus on developing small molecule BTK inhibitors and preclinical PDK1 inhibitors, respectively. Founded in 1998, Sunesis Pharmaceuticals is headquartered in South San Francisco, California.

IDEC Pharmaceuticals focuses on developing therapies for neurodegenerative, hematologic, and autoimmune diseases, with a particular emphasis on cancer treatments. Founded in 1986 by a group of researchers and entrepreneurs, including Ivor Royston and Howard Birndorf, the company originally aimed to develop and commercialize monoclonal antibodies. IDEC Pharmaceuticals gained recognition for its innovative approaches to treating conditions such as non-Hodgkin's lymphoma. In 2003, the company merged with Biogen, further expanding its capabilities in the biopharmaceutical industry.